Manulife (Manufacturers Life Insurance)’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $885K | Buy |
27,196
+2,924
| +12% | +$94K | ﹤0.01% | 1896 |
|
|
2025
Q4 | $854K | Buy |
24,272
+1,914
| +9% | +$67.8K | ﹤0.01% | 1931 |
|
|
2025
Q3 | $588K | Buy |
22,358
+768
| +4% | +$22.9K | ﹤0.01% | 2135 |
|
|
2025
Q2 | $572K | Sell |
21,590
-2,391
| -10% | -$62.9K | ﹤0.01% | 2119 |
|
|
2025
Q1 | $579K | Sell |
23,981
-695
| -3% | -$22K | ﹤0.01% | 2074 |
|
|
2024
Q4 | $993K | Buy |
24,676
+46
| +0.2% | +$2.62K | ﹤0.01% | 1910 |
|
|
2024
Q3 | $1.56M | Buy |
24,630
+4,156
| +20% | +$244K | ﹤0.01% | 1679 |
|
|
2024
Q2 | $1.09M | Sell |
20,474
-34,180
| -63% | -$2.24M | ﹤0.01% | 1817 |
|
|
2024
Q1 | $4.48M | Buy |
54,654
+7,581
| +16% | +$337K | ﹤0.01% | 1232 |
|
|
2023
Q4 | $876K | Sell |
47,073
-972
| -2% | -$12.7K | ﹤0.01% | 1861 |
|
|
2023
Q3 | $532K | Buy |
48,045
+11,049
| +30% | +$158K | ﹤0.01% | 2107 |
|
|
2023
Q2 | $600K | Buy |
+36,996
| New | +$775K | ﹤0.01% | 1931 |
|
|
2022
Q2 | – | Sell |
-31,790
| Closed | -$95.4K | – | 3146 |
|
|
2022
Q1 | $95.4K | Sell |
31,790
-8,179
| -20% | -$29.3K | ﹤0.01% | 2965 |
|
|
2021
Q4 | $184 | Buy |
39,969
+636
| +2% | +$3.56K | ﹤0.01% | 2922 |
|
|
2021
Q3 | $247K | Sell |
39,333
-2,732
| -6% | -$16.9K | ﹤0.01% | 2822 |
|
|
2021
Q2 | $252K | Buy |
42,065
+2,046
| +5% | +$12.1K | ﹤0.01% | 2946 |
|
|
2021
Q1 | $253K | Sell |
40,019
-1,738
| -4% | -$12.2K | ﹤0.01% | 2734 |
|
|
2020
Q4 | $235K | Buy |
41,757
+1,855
| +5% | +$11.2K | ﹤0.01% | 2676 |
|
|
2020
Q3 | $232K | Hold |
39,902
| – | – | ﹤0.01% | 2472 |
|
|
2020
Q2 | $290K | Sell |
39,902
-2,346
| -6% | -$15.6K | ﹤0.01% | 2283 |
|
|
2020
Q1 | $198K | Buy |
42,248
+2,458
| +6% | +$15.1K | ﹤0.01% | 2332 |
|
|
2019
Q4 | $319K | Sell |
39,790
-1,580
| -4% | -$11.5K | ﹤0.01% | 2306 |
|
|
2019
Q3 | $287K | Hold |
41,370
| – | – | ﹤0.01% | 2351 |
|
|
2019
Q2 | $343K | Buy |
41,370
+574
| +1% | +$4.91K | ﹤0.01% | 2283 |
|
|
2019
Q1 | $406K | Buy |
40,796
+5,254
| +15% | +$44K | ﹤0.01% | 2176 |
|
|
2018
Q4 | $272K | Buy |
35,542
+1,718
| +5% | +$20.5K | ﹤0.01% | 2197 |
|
|
2018
Q3 | $589K | Buy |
33,824
+496
| +1% | +$5.9K | ﹤0.01% | 2164 |
|
|
2018
Q2 | $316K | Buy |
33,328
+31,938
| +2,298% | +$212K | ﹤0.01% | 2741 |
|
|
2018
Q1 | $6K | Buy |
+1,390
| New | +$7.69K | ﹤0.01% | 4073 |
|
|
2017
Q3 | – | Sell |
-1,989
| Closed | -$2K | – | 4346 |
|
|
2017
Q2 | $2K | Buy |
1,989
+182
| +10% | +$232 | ﹤0.01% | 4142 |
|
|
2017
Q1 | $3K | Hold |
1,807
| – | – | ﹤0.01% | 3886 |
|
|
2016
Q4 | $2K | Hold |
1,807
| – | – | ﹤0.01% | 4128 |
|
|
2016
Q3 | $3K | Hold |
1,807
| – | – | ﹤0.01% | 4012 |
|
|
2016
Q2 | $2K | Hold |
1,807
| – | – | ﹤0.01% | 4021 |
|
|
2016
Q1 | $3K | Buy |
+1,807
| New | +$3.63K | ﹤0.01% | 3887 |
|
Other funds holding VKTX
VCM
VPM
Manulife (Manufacturers Life Insurance)'s VKTX Position: Q1 2026 in Review
Manulife (Manufacturers Life Insurance) increased its Viking Therapeutics (VKTX) stake by 12% in Q1 2026, buying an estimated $94K and bringing the position to 27,196 shares worth $885K. The position accounts for ﹤0.01% of the portfolio, ranked #1896.
Manulife (Manufacturers Life Insurance) first reported a position in VKTX in Q1 2016 and has held it in 35 quarters since. The position peaked at $4.48M in Q1 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Manulife (Manufacturers Life Insurance) held 27,196 shares of Viking Therapeutics worth $885K as of Q1 2026.
- Manulife (Manufacturers Life Insurance) bought 2,924 Viking Therapeutics shares in Q1 2026, an estimated $94K.
- Viking Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1896 holding.
- Manulife (Manufacturers Life Insurance) first reported a position in Viking Therapeutics in Q1 2016 and has held it in 35 quarters since.
- Manulife (Manufacturers Life Insurance)'s Viking Therapeutics position peaked at $4.48M in Q1 2024.
- 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.